Salt Lake City, Utah (March 14, 2019) The March issue of Regulatory Toxicology and Pharmacology
includes a study that gives an independent safety assessment of the 4Life Transfer Factor®
ingredient from cow colostrum. Publication is a requirement in 4Life’s pursuit of Generally Recognized as Safe (GRAS) status from the Food and Drug Administration (FDA).
Director of Scientific and Regulatory Affairs Dr. Paula Brock: “The article ‘Toxicological evaluations of colostrum ultrafiltrate,’ describes the research performed to demonstrate the safety of 4Life Transfer Factor. This represents a significant milestone in our pursuit of GRAS status and demonstrates our continued commitment to the integrity of 4Life products.”
The monthly peer-reviewed scientific journal covers a variety of legal and pharmacological issues of significance to scientists, academics, and the general public alike. This study is the most recent iteration in 4Life’s commitment to third-party validation.
4Life Founder and Chairman of the Board David Lisonbee: “The conclusion of this research is no surprise to us. However, it is necessary in our pursuit of GRAS status. As such, we are very pleased with the results.”
4Life has offices in 25 markets to serve a global network of independent distributors and their customers.
For more information:
Vice President, Corporate Communications